SCHEMBL27213620

SCHEMBL27213620

CN(Cc1ccc(Oc2ccc(CNc3c(N)c(Cl)nc4ccccc34)cc2)cc1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.42
EGFR P00533 1/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
RAD52 P43351 1/20 0.41
NCF1 P14598 1/20 0.41
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
TSPO P30536 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
TOP2A P11388 1/20 0.38
TOP2B Q02880 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30947342 0.90 APP (0.38) APPEGFRKMT2APOLBRAD52
SCHEMBL28802725 0.82 POLB (0.47) APPEGFRKMT2APOLBRAD52
SCHEMBL213444 0.81 APP (0.62) APPEGFRKMT2APOLBRAD52
SCHEMBL211489 0.80 POLB (0.51) APPKMT2APOLBRAD52KDM4E
SCHEMBL13968056 0.78 KMT2A (0.66) APPKMT2APOLBRAD52LMNA
SCHEMBL21013099 0.78 KMT2A (0.50) APPKMT2APOLBRAD52TOP2A
SCHEMBL29381485 0.78 KMT2A (0.50) APPKMT2APOLBRAD52TOP2A
SCHEMBL28872741 0.77 POLB (0.46) APPKMT2APOLBRAD52SMN1; SMN2
SCHEMBL29977361 0.77 EGFR (0.51) EGFRKMT2ALMNAMAPTSMN1; SMN2
SCHEMBL27744435 0.76 KMT2A (0.42) APPEGFRKMT2APOLBRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-05-09 US disclosed
WO-2022161420-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2022-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF TLR7, TLR1, TLR8 APP 3439/4885EGFR 2553/4885KMT2A 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.